###begin article-title 0
###xml 58 66 <span type="species:ncbi:9606">Patients</span>
Beclin-1 Expression is a Predictor of Clinical Outcome in Patients with Esophageal Squamous Cell Carcinoma and Correlated to Hypoxia-Inducible Factor (HIF)-1alpha Expression
###end article-title 0
###begin p 1
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 630 638 <span type="species:ncbi:9606">patients</span>
In the present study, we examined the relationship between Beclin-1 expression and HIF-1alpha expression in esophageal squamous cell carcinoma(ESCC). There was a loss of Beclin-1 protein expression in 33% of ESCCs. Beclin-1 expression significantly correlated with depth of invasion, lymph node metastasis and clinical stage. Among the 54 patients, The survival rate of the Beclin-1-positive group was better than that of the Beclin-1-negative group. Twenty-five of the 54 (46%) tumor specimens showed high levels of HIF-1alpha immunoreactivity. Beclin-1 expression was associated with HIF-1alpha expression. The survival rate of patients with Beclin-1-positive and HIF-1alpha-low tumors was significantly higher than that of the other groups. These results suggest that Beclin-1 and HIF-1alpha expression are important determinants of survival in ESCCs.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 840 841 840 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 843 844 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
Programmed cell death (PCD) is an essential and highly orchestrated process that plays a major role in morphogenesis and tissue homeostasis. Apoptosis, the type I PCD, is a well characterized caspase-dependent process. While autophagy, a vacuolar process of cytoplasmic degradation, is characterized by autophagic vacuoles accumulating, no apoptosis body forming, and no chromosome condensing and caspase independence. Thus, autophagic cell death is considered PCD type II [1, 2]. Autophagy is becoming an important area in cancer research, but data connecting cancer pathogenesis with autophagic cell death are limited. Whether autophagy in cancer cells causes death or protects cells is controversial. Malignant transformation is frequently associated with suppression of autophagy, however, the opposite scenario has also been reported [3, 4].
###end p 4
###begin p 5
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 385 388 385 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 440 443 440 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 629 630 629 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 648 649 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 853 854 853 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 95 100 <span type="species:ncbi:4932">yeast</span>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
###xml 158 163 <span type="species:ncbi:9606">human</span>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 1112 1117 <span type="species:ncbi:9606">human</span>
Beclin-1, an essential mediator of autophagy, was originally discovered during the course of a yeast two-hybrid screen of a mouse brain cDNA library [5]. The human Beclin-1 gene has been mapped to a tumor-susceptibility locus on chromosome 17q21 that is monoallelically deleted in up to 75% of ovarian cancers, 50% of breast cancers, and 40% of prostate cancers [6]. Moreover, Beclin-1-/- mutant mice die early in embryogenesis and Beclin-1+/- mutant mice suffer from a high incidence of spontaneous tumors, establishing that Beclin-1 is a critical component of mammalian autophagy and a role for autophagy in tumor suppression [7]. Liang's group [8] found a frequent loss of Beclin-1 protein expression in breast cancers, and suggested that tumor suppressor functions of Beclin-1 are lost in the cancer cells by loss of protein expression. Ahn et al. [9] demonstrated that Beclin-1 may play a role in tumorigenesis for the increased expression of Beclin-1 protein detected in the malignant colorectal and gastric epithelial cells. These contradictory results prompt us to analyse Beclin-1 protein expression in human esophageal cancer tissues.
###end p 5
###begin p 6
###xml 305 307 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 308 310 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 530 532 522 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 533 535 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 504 509 <span type="species:ncbi:10090">mouse</span>
###xml 648 653 <span type="species:ncbi:9606">human</span>
###xml 706 711 <span type="species:ncbi:9606">human</span>
###xml 968 975 <span type="species:ncbi:9606">patient</span>
HIF-1alpha has been found to play important roles in tumor growth and metastasis by regulating energy metabolism and inducing angiogenesis in the survival against cellular hypoxia. In various types of cancer, HIF-1alpha expression was reported to be correlated with tumor growth, invasion and metastases [10-13]. It was reported that autophagy associates with hypoxia. Autophagic cell death is induced by hypoxia in cancer cells with intact apoptotic machinery, and HIF-1 serves to regulate autophagy in mouse embryo fibroblasts [14-16]. However, there are no reports with respect to the relationship between Beclin-1 and HIF-1alpha expressions in human cancers. We therefore examined their expressions in human squamous cell carcinoma of the esophagus. The primary objective was to ascertain whether Beclin-1 plays a role in tumor development and progression associated with HIF-1alpha, as secondary endpoints, we evaluated the impact of their protein expressions on patient outcome.
###end p 6
###begin title 7
Materials and Methods
###end title 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and Tissues
###end title 8
###begin p 9
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
54 cases of esophagectomy specimens of primary esophageal squamous cell carcinoma (ESCC) were collected from the files of the Department of Pathology, West China Hospital, Sichuan University, dating from January 2003 to September 2004. All patients did not receive preoperative chemoradiotherapy. This study was conducted in accordance with ethical principles stated in the Declaration of Helsinki, 1996 and informed consent for using esophageal tissues was obtained from the patients or their families.
###end p 9
###begin p 10
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
To determine an accurate staging, pathology reports and clinical histories at the time of surgery were reviewed. The clinicopathologic stage was according to the International Union Against Cancer (UICC) TNM classification system [17]. Age, sex, tumor differentiation and TNM stage (T: depth of tumor invasion, N: lymph node metastasis, M: distant metastasis) were evaluated. The overall survival times of the patients were measured from the date of operation to the date of death or the last follow-up. The patients were 38 males and 16 females and ranged in age from 39 to 77 years (median: 61 years).
###end p 10
###begin title 11
Immunohistochemistry
###end title 11
###begin p 12
###xml 181 187 <span type="species:ncbi:9986">rabbit</span>
###xml 243 248 <span type="species:ncbi:10090">mouse</span>
Formalin-fixed, paraffin-embedded tissues (4 mum thick) were immunostained using a Labelled Streptavidin Biotin 2 (LSAB2) System (BioGenex i6000, USA). Beclin-1 was detected with a rabbit polyclonal antibody and HIF-1alpha was detected with a mouse monoclonal antibody Mab (1:80 dilution for the anti-Beclin-1 antibody or 1:100 dilution for the anti-HIF-1alpha antibody; Santa Cruz Biotechnology, Santa Cruz, USA). After deparaffinization and rehydration, tissue sections were incubated with 3% hydrogen peroxide in methanol for 30 min to block endogeneous peroxidase activity. The primary antibody reaction was carried out at 4degreesC overnight. Subsequent steps were performed according to the manufacturer's instructions. Diaminobenzidine-tetrahydrochloride (DAB) was used as the substrate to detect antigen-antibody binding, and the sections were counterstained with Mayer's haematoxylin.
###end p 12
###begin p 13
Beclin-1 and HIF-1alpha immunoreactivity were detected in normal epithelial cells of esophagus and squamous cell carcinoma tissues. Expression of Beclin-1 was defined as positive if distinct staining of the cytoplasm or cytomembrane was observed in at least 10% of tumor cells.
###end p 13
###begin p 14
HIF-1alpha immunoreactivity was present in cytoplasm. The percentages of cancer cells with cytoplasmic HIF-1alpha localisation were assessed separately in all optical fields. The mean value of the percentages obtained from all optical fields examined in each case was used to calculate the cytoplasmic scores for each case. These scores were used to calculate the overall mean value and range of the percentages of cells with HIF-1alpha localisation. The mean values for cytoplasmic expression of HIF-1alpha were used as the cut-off points to define two groups: high and low HIF-1alpha expression.
###end p 14
###begin title 15
Statistical Analysis
###end title 15
###begin p 16
###xml 442 443 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Statistical evaluation was performed using the SPSS software package (SPSS 16.0, SPSS Inc., Chicago, USA). The Chi-square test was used to analyze the correlation between Beclin-1 or HIF-1alpha expression and clinicopathologic features. Cumulative survival rate was calculated by the Kaplan-Meier method, and the significance of differences in survival rate was analyzed by the log-rank test. The level of statistical significance was set at p < 0.05.
###end p 16
###begin title 17
Results
###end title 17
###begin title 18
Relationship between Beclin-1 Expression and Clinicopathological Features
###end title 18
###begin p 19
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 670 676 670 676 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 771 772 767 768 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 858 859 854 855 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 912 913 908 909 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 996 997 992 993 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1081 1082 1073 1074 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1146 1147 1134 1135 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1224 1225 1208 1209 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1227 1228 1211 1212 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1233 1234 1217 1218 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1242 1243 1226 1227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1248 1249 1232 1233 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1257 1258 1241 1242 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 676 1264 676 1248 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="20">Immunohistochemical analysis of Beclin-1 and HIF-1&#945; in esophageal squamous cell carcinoma. <bold>a</bold> Positive Beclin-1 immunoreactivity in cytoplasm of normal squamous epithelial cells. <bold>b</bold> Negative Beclin-1 immunoreactivity in tumour cells. <bold>c</bold> Positive Beclin-1 immunoreactivity in cytoplasm and cytomembrane of tumour cells. <bold>d</bold> In normal squamous epithelial cells, HIF-1&#945; immunoreactivity was not detected. <bold>e</bold> Weak HIF-1&#945; immunoreactivity in cytoplasm of tumour cells. <bold>f</bold> Strong HIF-1&#945; immunoreactivity in tumour cells. Original magnification: <bold>a</bold>, <bold>e</bold> and <bold>f</bold>, &#215;200; <bold>b</bold> and <bold>d</bold>, &#215;100; <bold>c</bold>, &#215;400</p>
###xml 676 1264 676 1248 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="20">Immunohistochemical analysis of Beclin-1 and HIF-1&#945; in esophageal squamous cell carcinoma. <bold>a</bold> Positive Beclin-1 immunoreactivity in cytoplasm of normal squamous epithelial cells. <bold>b</bold> Negative Beclin-1 immunoreactivity in tumour cells. <bold>c</bold> Positive Beclin-1 immunoreactivity in cytoplasm and cytomembrane of tumour cells. <bold>d</bold> In normal squamous epithelial cells, HIF-1&#945; immunoreactivity was not detected. <bold>e</bold> Weak HIF-1&#945; immunoreactivity in cytoplasm of tumour cells. <bold>f</bold> Strong HIF-1&#945; immunoreactivity in tumour cells. Original magnification: <bold>a</bold>, <bold>e</bold> and <bold>f</bold>, &#215;200; <bold>b</bold> and <bold>d</bold>, &#215;100; <bold>c</bold>, &#215;400</p></caption>
###xml 1264 1264 1248 1248 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12253_2008_9143_Fig1_HTML" id="MO1"/>
###xml 670 1264 670 1248 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="20">Immunohistochemical analysis of Beclin-1 and HIF-1&#945; in esophageal squamous cell carcinoma. <bold>a</bold> Positive Beclin-1 immunoreactivity in cytoplasm of normal squamous epithelial cells. <bold>b</bold> Negative Beclin-1 immunoreactivity in tumour cells. <bold>c</bold> Positive Beclin-1 immunoreactivity in cytoplasm and cytomembrane of tumour cells. <bold>d</bold> In normal squamous epithelial cells, HIF-1&#945; immunoreactivity was not detected. <bold>e</bold> Weak HIF-1&#945; immunoreactivity in cytoplasm of tumour cells. <bold>f</bold> Strong HIF-1&#945; immunoreactivity in tumour cells. Original magnification: <bold>a</bold>, <bold>e</bold> and <bold>f</bold>, &#215;200; <bold>b</bold> and <bold>d</bold>, &#215;100; <bold>c</bold>, &#215;400</p></caption><graphic position="anchor" xlink:href="12253_2008_9143_Fig1_HTML" id="MO1"/></fig>
###xml 1264 1271 1248 1255 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1271 1331 1255 1315 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21">Clinicopathological features and Beclin-1 expression in ESCC</p>
###xml 1271 1331 1255 1315 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21">Clinicopathological features and Beclin-1 expression in ESCC</p></caption>
###xml 1331 1340 1315 1324 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Variables</th>
###xml 1340 1352 1324 1336 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">No. of cases</th>
###xml 1352 1371 1336 1355 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Beclin-1 expression</th>
###xml 1371 1372 1355 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1371 1378 1355 1362 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>P</italic> value</th>
###xml 1331 1378 1315 1362 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">Beclin-1 expression</th><th rowspan="2"><italic>P</italic> value</th></tr>
###xml 1378 1386 1362 1370 <th xmlns:xlink="http://www.w3.org/1999/xlink">Positive</th>
###xml 1386 1394 1370 1378 <th xmlns:xlink="http://www.w3.org/1999/xlink">Negative</th>
###xml 1378 1394 1362 1378 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Positive</th><th>Negative</th></tr>
###xml 1331 1394 1315 1378 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">Beclin-1 expression</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Positive</th><th>Negative</th></tr></thead>
###xml 1394 1400 1378 1384 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Gender</td>
###xml 1394 1400 1378 1384 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Gender</td></tr>
###xml 1400 1405 1384 1389 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Male</td>
###xml 1405 1407 1389 1391 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 1407 1409 1391 1393 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 1409 1411 1393 1395 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14</td>
###xml 1411 1416 1395 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.399</td>
###xml 1400 1416 1384 1400 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Male</td><td char="." align="char">38</td><td char="." align="char">24</td><td char="." align="char">14</td><td char="." align="char">0.399</td></tr>
###xml 1416 1423 1400 1407 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Female</td>
###xml 1423 1425 1407 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 1425 1427 1409 1411 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 1427 1428 1411 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 1428 1428 1412 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1416 1428 1400 1412 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Female</td><td char="." align="char">16</td><td char="." align="char">12</td><td char="." align="char">4</td><td char="." align="char"/></tr>
###xml 1428 1439 1412 1423 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Age (years)</td>
###xml 1428 1439 1412 1423 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Age (years)</td></tr>
###xml 1439 1443 1423 1427 <td xmlns:xlink="http://www.w3.org/1999/xlink"> &lt;60</td>
###xml 1443 1445 1427 1429 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 1445 1447 1429 1431 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 1447 1449 1431 1433 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1449 1453 1433 1437 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.00</td>
###xml 1439 1453 1423 1437 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">20</td><td char="." align="char">10</td><td char="." align="char">1.00</td></tr>
###xml 1453 1459 1437 1441 <td xmlns:xlink="http://www.w3.org/1999/xlink"> &#8805;60</td>
###xml 1459 1461 1441 1443 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 1461 1463 1443 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 1463 1464 1445 1446 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 1464 1464 1446 1446 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1453 1464 1437 1446 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr>
###xml 1464 1479 1446 1461 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Differentiation</td>
###xml 1464 1479 1446 1461 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Differentiation</td></tr>
###xml 1479 1484 1461 1466 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Well</td>
###xml 1484 1486 1466 1468 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 1486 1488 1468 1470 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1488 1489 1470 1471 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1489 1494 1471 1476 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.351</td>
###xml 1479 1494 1461 1476 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.351</td></tr>
###xml 1494 1503 1476 1485 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Moderate</td>
###xml 1503 1505 1485 1487 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 1505 1507 1487 1489 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 1507 1508 1489 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7</td>
###xml 1508 1508 1490 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1494 1508 1476 1490 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr>
###xml 1508 1513 1490 1495 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Poor</td>
###xml 1513 1515 1495 1497 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 1515 1517 1497 1499 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 1517 1518 1499 1500 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 1518 1518 1500 1500 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1508 1518 1490 1500 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Poor</td><td char="." align="char">22</td><td char="." align="char">13</td><td char="." align="char">9</td><td char="." align="char"/></tr>
###xml 1518 1525 1500 1507 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">T stage</td>
###xml 1518 1525 1500 1507 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">T stage</td></tr>
###xml 1525 1532 1507 1514 <td xmlns:xlink="http://www.w3.org/1999/xlink"> T1, T2</td>
###xml 1532 1534 1514 1516 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 1534 1536 1516 1518 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23</td>
###xml 1536 1537 1518 1519 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1537 1542 1519 1524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.001</td>
###xml 1525 1542 1507 1524 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">23</td><td char="." align="char">2</td><td char="." align="char">0.001</td></tr>
###xml 1542 1549 1524 1531 <td xmlns:xlink="http://www.w3.org/1999/xlink"> T3, T4</td>
###xml 1549 1551 1531 1533 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">29</td>
###xml 1551 1553 1533 1535 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 1553 1555 1535 1537 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 1555 1555 1537 1537 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1542 1555 1524 1537 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">13</td><td char="." align="char">16</td><td char="." align="char"/></tr>
###xml 1555 1562 1537 1544 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">N stage</td>
###xml 1555 1562 1537 1544 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">N stage</td></tr>
###xml 1562 1565 1544 1547 <td xmlns:xlink="http://www.w3.org/1999/xlink"> N0</td>
###xml 1565 1567 1547 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 1567 1569 1549 1551 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 1569 1570 1551 1552 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 1570 1576 1552 1558 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1562 1576 1544 1558 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> N0</td><td char="." align="char">26</td><td char="." align="char">24</td><td char="." align="char">2</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1576 1579 1558 1561 <td xmlns:xlink="http://www.w3.org/1999/xlink"> N1</td>
###xml 1579 1581 1561 1563 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28</td>
###xml 1581 1583 1563 1565 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 1583 1585 1565 1567 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 1585 1585 1567 1567 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1576 1585 1558 1567 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr>
###xml 1585 1599 1567 1581 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Clinical stage</td>
###xml 1585 1599 1567 1581 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Clinical stage</td></tr>
###xml 1599 1605 1581 1587 <td xmlns:xlink="http://www.w3.org/1999/xlink"> I, II</td>
###xml 1605 1607 1587 1589 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 1607 1609 1589 1591 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1609 1610 1591 1592 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1610 1616 1592 1598 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 1599 1616 1581 1598 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> I, II</td><td char="." align="char">22</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr>
###xml 1616 1624 1598 1606 <td xmlns:xlink="http://www.w3.org/1999/xlink"> III, IV</td>
###xml 1624 1626 1606 1608 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">32</td>
###xml 1626 1628 1608 1610 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 1628 1630 1610 1612 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 1630 1630 1612 1612 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 1616 1630 1598 1612 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">15</td><td char="." align="char">17</td><td char="." align="char"/></tr>
###xml 1394 1630 1378 1612 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td char="." align="char">38</td><td char="." align="char">24</td><td char="." align="char">14</td><td char="." align="char">0.399</td></tr><tr><td> Female</td><td char="." align="char">16</td><td char="." align="char">12</td><td char="." align="char">4</td><td char="." align="char"/></tr><tr><td colspan="5">Age (years)</td></tr><tr><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">20</td><td char="." align="char">10</td><td char="." align="char">1.00</td></tr><tr><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr><tr><td colspan="5">Differentiation</td></tr><tr><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.351</td></tr><tr><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr><tr><td> Poor</td><td char="." align="char">22</td><td char="." align="char">13</td><td char="." align="char">9</td><td char="." align="char"/></tr><tr><td colspan="5">T stage</td></tr><tr><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">23</td><td char="." align="char">2</td><td char="." align="char">0.001</td></tr><tr><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">13</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">N stage</td></tr><tr><td> N0</td><td char="." align="char">26</td><td char="." align="char">24</td><td char="." align="char">2</td><td char="." align="char">&lt;0.001</td></tr><tr><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">Clinical stage</td></tr><tr><td> I, II</td><td char="." align="char">22</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr><tr><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">15</td><td char="." align="char">17</td><td char="." align="char"/></tr></tbody>
###xml 1331 1630 1315 1612 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">Beclin-1 expression</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Positive</th><th>Negative</th></tr></thead><tbody><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td char="." align="char">38</td><td char="." align="char">24</td><td char="." align="char">14</td><td char="." align="char">0.399</td></tr><tr><td> Female</td><td char="." align="char">16</td><td char="." align="char">12</td><td char="." align="char">4</td><td char="." align="char"/></tr><tr><td colspan="5">Age (years)</td></tr><tr><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">20</td><td char="." align="char">10</td><td char="." align="char">1.00</td></tr><tr><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr><tr><td colspan="5">Differentiation</td></tr><tr><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.351</td></tr><tr><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr><tr><td> Poor</td><td char="." align="char">22</td><td char="." align="char">13</td><td char="." align="char">9</td><td char="." align="char"/></tr><tr><td colspan="5">T stage</td></tr><tr><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">23</td><td char="." align="char">2</td><td char="." align="char">0.001</td></tr><tr><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">13</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">N stage</td></tr><tr><td> N0</td><td char="." align="char">26</td><td char="." align="char">24</td><td char="." align="char">2</td><td char="." align="char">&lt;0.001</td></tr><tr><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">Clinical stage</td></tr><tr><td> I, II</td><td char="." align="char">22</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr><tr><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">15</td><td char="." align="char">17</td><td char="." align="char"/></tr></tbody></table>
###xml 1264 1630 1248 1612 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="21">Clinicopathological features and Beclin-1 expression in ESCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">Beclin-1 expression</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Positive</th><th>Negative</th></tr></thead><tbody><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td char="." align="char">38</td><td char="." align="char">24</td><td char="." align="char">14</td><td char="." align="char">0.399</td></tr><tr><td> Female</td><td char="." align="char">16</td><td char="." align="char">12</td><td char="." align="char">4</td><td char="." align="char"/></tr><tr><td colspan="5">Age (years)</td></tr><tr><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">20</td><td char="." align="char">10</td><td char="." align="char">1.00</td></tr><tr><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr><tr><td colspan="5">Differentiation</td></tr><tr><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.351</td></tr><tr><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr><tr><td> Poor</td><td char="." align="char">22</td><td char="." align="char">13</td><td char="." align="char">9</td><td char="." align="char"/></tr><tr><td colspan="5">T stage</td></tr><tr><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">23</td><td char="." align="char">2</td><td char="." align="char">0.001</td></tr><tr><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">13</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">N stage</td></tr><tr><td> N0</td><td char="." align="char">26</td><td char="." align="char">24</td><td char="." align="char">2</td><td char="." align="char">&lt;0.001</td></tr><tr><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">Clinical stage</td></tr><tr><td> I, II</td><td char="." align="char">22</td><td char="." align="char">21</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr><tr><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">15</td><td char="." align="char">17</td><td char="." align="char"/></tr></tbody></table></table-wrap>
Of the 54 ESCCs, immunoreactivity for Beclin-1 was not detected in 18 cases (Fig. 1b). 36 (66.7%) showed positive Beclin-1 immunoreactivity in the cytoplasm and cytomembrane of cancer cells (Fig. 1c). While analyzing clinicopathological factors, depth of invasion, lymph node metastasis and clinical stage showed statistically significant correlations with Beclin-1 expression; however, there was no significant difference in Beclin-1 expression with respect to other characteristics (sex, age and differentiation) (Table 1). Beclin-1 was displayed positive immunoreactivity in normal epithelial cells of all cases adjacent to squamous cell carcinoma tissues (Fig. 1a). Fig. 1Immunohistochemical analysis of Beclin-1 and HIF-1alpha in esophageal squamous cell carcinoma. a Positive Beclin-1 immunoreactivity in cytoplasm of normal squamous epithelial cells. b Negative Beclin-1 immunoreactivity in tumour cells. c Positive Beclin-1 immunoreactivity in cytoplasm and cytomembrane of tumour cells. d In normal squamous epithelial cells, HIF-1alpha immunoreactivity was not detected. e Weak HIF-1alpha immunoreactivity in cytoplasm of tumour cells. f Strong HIF-1alpha immunoreactivity in tumour cells. Original magnification: a, e and f, x200; b and d, x100; c, x400Table 1Clinicopathological features and Beclin-1 expression in ESCCVariablesNo. of casesBeclin-1 expressionP valuePositiveNegativeGender Male3824140.399 Female16124Age (years) <603020101.00 >/=6024168Differentiation Well121020.351 Moderate20137 Poor22139T stage T1, T2252320.001 T3, T4291316N stage N026242<0.001 N1281216Clinical stage I, II22211<0.001 III, IV321517
###end p 19
###begin p 20
###xml 95 96 91 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 182 183 178 179 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 236 237 232 233 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 320 321 316 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 405 406 397 398 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 470 471 458 459 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 548 549 532 533 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 551 552 535 536 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 557 558 541 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 566 567 550 551 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 572 573 556 557 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 581 582 565 566 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
Immunohistochemical analysis of Beclin-1 and HIF-1alpha in esophageal squamous cell carcinoma. a Positive Beclin-1 immunoreactivity in cytoplasm of normal squamous epithelial cells. b Negative Beclin-1 immunoreactivity in tumour cells. c Positive Beclin-1 immunoreactivity in cytoplasm and cytomembrane of tumour cells. d In normal squamous epithelial cells, HIF-1alpha immunoreactivity was not detected. e Weak HIF-1alpha immunoreactivity in cytoplasm of tumour cells. f Strong HIF-1alpha immunoreactivity in tumour cells. Original magnification: a, e and f, x200; b and d, x100; c, x400
###end p 20
###begin p 21
Clinicopathological features and Beclin-1 expression in ESCC
###end p 21
###begin title 22
Relationship between HIF-1alpha Expression and Clinicopathological Features
###end title 22
###begin p 23
###xml 89 90 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 188 189 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 546 547 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 550 557 530 537 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 557 619 537 595 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">Clinicopathological features and HIF-1&#945; expression in ESCC</p>
###xml 557 619 537 595 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24">Clinicopathological features and HIF-1&#945; expression in ESCC</p></caption>
###xml 619 628 595 604 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Variables</th>
###xml 628 640 604 616 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">No. of cases</th>
###xml 640 661 616 633 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">HIF-1&#945; expression</th>
###xml 661 662 633 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 661 668 633 640 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>P</italic> value</th>
###xml 619 668 595 640 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">HIF-1&#945; expression</th><th rowspan="2"><italic>P</italic> value</th></tr>
###xml 668 671 640 643 <th xmlns:xlink="http://www.w3.org/1999/xlink">Low</th>
###xml 671 675 643 647 <th xmlns:xlink="http://www.w3.org/1999/xlink">High</th>
###xml 668 675 640 647 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Low</th><th>High</th></tr>
###xml 619 675 595 647 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">HIF-1&#945; expression</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Low</th><th>High</th></tr></thead>
###xml 675 681 647 653 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Gender</td>
###xml 675 681 647 653 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Gender</td></tr>
###xml 681 686 653 658 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Male</td>
###xml 686 688 658 660 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 688 690 660 662 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23</td>
###xml 690 692 662 664 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 692 697 664 669 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.121</td>
###xml 681 697 653 669 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Male</td><td char="." align="char">38</td><td char="." align="char">23</td><td char="." align="char">15</td><td char="." align="char">0.121</td></tr>
###xml 697 704 669 676 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Female</td>
###xml 704 706 676 678 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 706 707 678 679 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 707 709 679 681 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 709 709 681 681 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 697 709 669 681 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Female</td><td char="." align="char">16</td><td char="." align="char">6</td><td char="." align="char">10</td><td char="." align="char"/></tr>
###xml 709 720 681 692 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Age (years)</td>
###xml 709 720 681 692 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Age (years)</td></tr>
###xml 720 724 692 696 <td xmlns:xlink="http://www.w3.org/1999/xlink"> &lt;60</td>
###xml 724 726 696 698 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 726 728 698 700 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 728 730 700 702 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 730 735 702 707 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.088</td>
###xml 720 735 692 707 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">13</td><td char="." align="char">17</td><td char="." align="char">0.088</td></tr>
###xml 735 741 707 711 <td xmlns:xlink="http://www.w3.org/1999/xlink"> &#8805;60</td>
###xml 741 743 711 713 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 743 745 713 715 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 745 746 715 716 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 746 746 716 716 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 735 746 707 716 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr>
###xml 746 761 716 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Differentiation</td>
###xml 746 761 716 731 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Differentiation</td></tr>
###xml 761 766 731 736 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Well</td>
###xml 766 768 736 738 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 768 770 738 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 770 771 740 741 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 771 776 741 746 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.003</td>
###xml 761 776 731 746 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.003</td></tr>
###xml 776 785 746 755 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Moderate</td>
###xml 785 787 755 757 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 787 789 757 759 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 789 790 759 760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7</td>
###xml 790 790 760 760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 776 790 746 760 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr>
###xml 790 795 760 765 <td xmlns:xlink="http://www.w3.org/1999/xlink"> Poor</td>
###xml 795 797 765 767 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 797 798 767 768 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 798 800 768 770 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 800 800 770 770 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 790 800 760 770 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> Poor</td><td char="." align="char">22</td><td char="." align="char">6</td><td char="." align="char">16</td><td char="." align="char"/></tr>
###xml 800 807 770 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">T stage</td>
###xml 800 807 770 777 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">T stage</td></tr>
###xml 807 814 777 784 <td xmlns:xlink="http://www.w3.org/1999/xlink"> T1, T2</td>
###xml 814 816 784 786 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 816 818 786 788 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 818 819 788 789 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 819 825 789 795 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.001</td>
###xml 807 825 777 795 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">24</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr>
###xml 825 832 795 802 <td xmlns:xlink="http://www.w3.org/1999/xlink"> T3, T4</td>
###xml 832 834 802 804 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">29</td>
###xml 834 835 804 805 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 835 837 805 807 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 837 837 807 807 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 825 837 795 807 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">5</td><td char="." align="char">24</td><td char="." align="char"/></tr>
###xml 837 844 807 814 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">N stage</td>
###xml 837 844 807 814 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">N stage</td></tr>
###xml 844 847 814 817 <td xmlns:xlink="http://www.w3.org/1999/xlink"> N0</td>
###xml 847 849 817 819 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 849 851 819 821 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 851 852 821 822 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9</td>
###xml 852 857 822 827 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.097</td>
###xml 844 857 814 827 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> N0</td><td char="." align="char">26</td><td char="." align="char">17</td><td char="." align="char">9</td><td char="." align="char">0.097</td></tr>
###xml 857 860 827 830 <td xmlns:xlink="http://www.w3.org/1999/xlink"> N1</td>
###xml 860 862 830 832 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28</td>
###xml 862 864 832 834 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 864 866 834 836 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 866 866 836 836 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 857 866 827 836 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr>
###xml 866 880 836 850 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Clinical stage</td>
###xml 866 880 836 850 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="5">Clinical stage</td></tr>
###xml 880 886 850 856 <td xmlns:xlink="http://www.w3.org/1999/xlink"> I, II</td>
###xml 886 888 856 858 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 888 890 858 860 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 890 891 860 861 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 891 896 861 866 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.004</td>
###xml 880 896 850 866 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> I, II</td><td char="." align="char">22</td><td char="." align="char">17</td><td char="." align="char">5</td><td char="." align="char">0.004</td></tr>
###xml 896 904 866 874 <td xmlns:xlink="http://www.w3.org/1999/xlink"> III, IV</td>
###xml 904 906 874 876 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">32</td>
###xml 906 908 876 878 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12</td>
###xml 908 910 878 880 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 910 910 880 880 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 896 910 866 880 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">12</td><td char="." align="char">20</td><td char="." align="char"/></tr>
###xml 675 910 647 880 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td char="." align="char">38</td><td char="." align="char">23</td><td char="." align="char">15</td><td char="." align="char">0.121</td></tr><tr><td> Female</td><td char="." align="char">16</td><td char="." align="char">6</td><td char="." align="char">10</td><td char="." align="char"/></tr><tr><td colspan="5">Age (years)</td></tr><tr><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">13</td><td char="." align="char">17</td><td char="." align="char">0.088</td></tr><tr><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr><tr><td colspan="5">Differentiation</td></tr><tr><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.003</td></tr><tr><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr><tr><td> Poor</td><td char="." align="char">22</td><td char="." align="char">6</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">T stage</td></tr><tr><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">24</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr><tr><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">5</td><td char="." align="char">24</td><td char="." align="char"/></tr><tr><td colspan="5">N stage</td></tr><tr><td> N0</td><td char="." align="char">26</td><td char="." align="char">17</td><td char="." align="char">9</td><td char="." align="char">0.097</td></tr><tr><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">Clinical stage</td></tr><tr><td> I, II</td><td char="." align="char">22</td><td char="." align="char">17</td><td char="." align="char">5</td><td char="." align="char">0.004</td></tr><tr><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">12</td><td char="." align="char">20</td><td char="." align="char"/></tr></tbody>
###xml 619 910 595 880 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">HIF-1&#945; expression</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Low</th><th>High</th></tr></thead><tbody><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td char="." align="char">38</td><td char="." align="char">23</td><td char="." align="char">15</td><td char="." align="char">0.121</td></tr><tr><td> Female</td><td char="." align="char">16</td><td char="." align="char">6</td><td char="." align="char">10</td><td char="." align="char"/></tr><tr><td colspan="5">Age (years)</td></tr><tr><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">13</td><td char="." align="char">17</td><td char="." align="char">0.088</td></tr><tr><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr><tr><td colspan="5">Differentiation</td></tr><tr><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.003</td></tr><tr><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr><tr><td> Poor</td><td char="." align="char">22</td><td char="." align="char">6</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">T stage</td></tr><tr><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">24</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr><tr><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">5</td><td char="." align="char">24</td><td char="." align="char"/></tr><tr><td colspan="5">N stage</td></tr><tr><td> N0</td><td char="." align="char">26</td><td char="." align="char">17</td><td char="." align="char">9</td><td char="." align="char">0.097</td></tr><tr><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">Clinical stage</td></tr><tr><td> I, II</td><td char="." align="char">22</td><td char="." align="char">17</td><td char="." align="char">5</td><td char="." align="char">0.004</td></tr><tr><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">12</td><td char="." align="char">20</td><td char="." align="char"/></tr></tbody></table>
###xml 550 910 530 880 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="24">Clinicopathological features and HIF-1&#945; expression in ESCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variables</th><th rowspan="2">No. of cases</th><th colspan="2">HIF-1&#945; expression</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Low</th><th>High</th></tr></thead><tbody><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td char="." align="char">38</td><td char="." align="char">23</td><td char="." align="char">15</td><td char="." align="char">0.121</td></tr><tr><td> Female</td><td char="." align="char">16</td><td char="." align="char">6</td><td char="." align="char">10</td><td char="." align="char"/></tr><tr><td colspan="5">Age (years)</td></tr><tr><td> &lt;60</td><td char="." align="char">30</td><td char="." align="char">13</td><td char="." align="char">17</td><td char="." align="char">0.088</td></tr><tr><td> &#8805;60</td><td char="." align="char">24</td><td char="." align="char">16</td><td char="." align="char">8</td><td char="." align="char"/></tr><tr><td colspan="5">Differentiation</td></tr><tr><td> Well</td><td char="." align="char">12</td><td char="." align="char">10</td><td char="." align="char">2</td><td char="." align="char">0.003</td></tr><tr><td> Moderate</td><td char="." align="char">20</td><td char="." align="char">13</td><td char="." align="char">7</td><td char="." align="char"/></tr><tr><td> Poor</td><td char="." align="char">22</td><td char="." align="char">6</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">T stage</td></tr><tr><td> T1, T2</td><td char="." align="char">25</td><td char="." align="char">24</td><td char="." align="char">1</td><td char="." align="char">&lt;0.001</td></tr><tr><td> T3, T4</td><td char="." align="char">29</td><td char="." align="char">5</td><td char="." align="char">24</td><td char="." align="char"/></tr><tr><td colspan="5">N stage</td></tr><tr><td> N0</td><td char="." align="char">26</td><td char="." align="char">17</td><td char="." align="char">9</td><td char="." align="char">0.097</td></tr><tr><td> N1</td><td char="." align="char">28</td><td char="." align="char">12</td><td char="." align="char">16</td><td char="." align="char"/></tr><tr><td colspan="5">Clinical stage</td></tr><tr><td> I, II</td><td char="." align="char">22</td><td char="." align="char">17</td><td char="." align="char">5</td><td char="." align="char">0.004</td></tr><tr><td> III, IV</td><td char="." align="char">32</td><td char="." align="char">12</td><td char="." align="char">20</td><td char="." align="char"/></tr></tbody></table></table-wrap>
HIF-1alpha immunoreactivity was not detected in normal squamous cells of esophagus (Fig. 1d). HIF-1alpha staining was observed mainly in the cytoplasm of the esophageal cancer cells (Fig. 1e, f). The mean percentage of cells with cytoplasmic HIF-1alpha immunoreactivity was 28.2% (range 5-80%). On the basis of the criteria described in Section 2, 25 of the 54 ESCCs(46.3%) were judged to have high HIF-1alpha expression. HIF-1alpha immunoreactivity was correlated significantly with differentiation, depth of invasion, and clinical stage (Table 2). Table 2Clinicopathological features and HIF-1alpha expression in ESCCVariablesNo. of casesHIF-1alpha expressionP valueLowHighGender Male3823150.121 Female16610Age (years) <603013170.088 >/=6024168Differentiation Well121020.003 Moderate20137 Poor22616T stage T1, T225241<0.001 T3, T429524N stage N0261790.097 N1281216Clinical stage I, II221750.004 III, IV321220
###end p 23
###begin p 24
Clinicopathological features and HIF-1alpha expression in ESCC
###end p 24
###begin title 25
Relationship between Beclin-1 and HIF-1alpha Expression
###end title 25
###begin p 26
###xml 404 405 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 421 422 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 425 432 401 408 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 432 500 408 472 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Coincidental expressions of Beclin-1 and HIF-1&#945; proteins in ESCC</p>
###xml 432 500 408 472 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Coincidental expressions of Beclin-1 and HIF-1&#945; proteins in ESCC</p></caption>
###xml 500 501 472 473 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">&#160;</th>
###xml 501 509 473 481 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Beclin-1</th>
###xml 509 510 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 509 516 481 488 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>P</italic> value</th>
###xml 500 516 472 488 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">&#160;</th><th colspan="2">Beclin-1</th><th rowspan="2"><italic>P</italic> value</th></tr>
###xml 516 524 488 496 <th xmlns:xlink="http://www.w3.org/1999/xlink">Positive</th>
###xml 524 532 496 504 <th xmlns:xlink="http://www.w3.org/1999/xlink">Negative</th>
###xml 516 532 488 504 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Positive</th><th>Negative</th></tr>
###xml 500 532 472 504 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">&#160;</th><th colspan="2">Beclin-1</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Positive</th><th>Negative</th></tr></thead>
###xml 532 546 504 514 <td xmlns:xlink="http://www.w3.org/1999/xlink">Low HIF-1&#945;</td>
###xml 546 556 514 524 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">24 (36.9%)</td>
###xml 556 565 524 533 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">5 (7.69%)</td>
###xml 565 570 533 538 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.001</td>
###xml 532 570 504 538 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Low HIF-1&#945;</td><td char="(" align="char">24 (36.9%)</td><td char="(" align="char">5 (7.69%)</td><td char="." align="char">0.001</td></tr>
###xml 570 585 538 549 <td xmlns:xlink="http://www.w3.org/1999/xlink">High HIF-1&#945;</td>
###xml 585 595 549 559 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">12 (18.5%)</td>
###xml 595 603 559 567 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="(" align="char">13 (20%)</td>
###xml 603 603 567 567 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char"/>
###xml 570 603 538 567 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>High HIF-1&#945;</td><td char="(" align="char">12 (18.5%)</td><td char="(" align="char">13 (20%)</td><td char="." align="char"/></tr>
###xml 532 603 504 567 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Low HIF-1&#945;</td><td char="(" align="char">24 (36.9%)</td><td char="(" align="char">5 (7.69%)</td><td char="." align="char">0.001</td></tr><tr><td>High HIF-1&#945;</td><td char="(" align="char">12 (18.5%)</td><td char="(" align="char">13 (20%)</td><td char="." align="char"/></tr></tbody>
###xml 500 603 472 567 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Beclin-1</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Positive</th><th>Negative</th></tr></thead><tbody><tr><td>Low HIF-1&#945;</td><td char="(" align="char">24 (36.9%)</td><td char="(" align="char">5 (7.69%)</td><td char="." align="char">0.001</td></tr><tr><td>High HIF-1&#945;</td><td char="(" align="char">12 (18.5%)</td><td char="(" align="char">13 (20%)</td><td char="." align="char"/></tr></tbody></table>
###xml 425 603 401 567 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="27">Coincidental expressions of Beclin-1 and HIF-1&#945; proteins in ESCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">&#160;</th><th colspan="2">Beclin-1</th><th rowspan="2"><italic>P</italic> value</th></tr><tr><th>Positive</th><th>Negative</th></tr></thead><tbody><tr><td>Low HIF-1&#945;</td><td char="(" align="char">24 (36.9%)</td><td char="(" align="char">5 (7.69%)</td><td char="." align="char">0.001</td></tr><tr><td>High HIF-1&#945;</td><td char="(" align="char">12 (18.5%)</td><td char="(" align="char">13 (20%)</td><td char="." align="char"/></tr></tbody></table></table-wrap>
We analysed the association between Beclin-1 and HIF-1alpha protein expression. In the 36 ESCCs marked as Beclin-1-positive tumors, 24 were low-HIF-1alpha and 12 were high-HIF-1alpha. Whereas, in the 18 ESCCs classified as Beclin-1-negative tumors, the low-HIF-1alpha and high-HIF-1alpha tumors were 5 and 13, respectively. A significant association was found between Beclin-1 and HIF-1alpha expression (P = 0.001, Table 3). Table 3Coincidental expressions of Beclin-1 and HIF-1alpha proteins in ESCC Beclin-1P valuePositiveNegativeLow HIF-1alpha24 (36.9%)5 (7.69%)0.001High HIF-1alpha12 (18.5%)13 (20%)
###end p 26
###begin p 27
Coincidental expressions of Beclin-1 and HIF-1alpha proteins in ESCC
###end p 27
###begin title 28
Cumulative Kaplan-Meier Survival Curve
###end title 28
###begin p 29
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 512 513 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 650 651 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 713 714 701 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 727 728 715 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 732 738 720 726 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 779 780 767 768 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 861 862 849 850 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 938 939 918 919 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 738 1079 726 1051 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Cumulative Kaplan&#8211;Meier survival curves. <bold>a</bold> Curves for patients with Beclin-1-positive tumors and Beclin-1-negative tumors. <bold>b</bold> Curves for patients with HIF-1&#945;-low tumors and HIF-1&#945;-high tumors. <bold>c</bold> Curves for patients with Beclin-1-positive and HIF-1&#945;-low tumors compared to patients with Beclin-1-negative and HIF-1&#945;-high tumors</p>
###xml 738 1079 726 1051 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Cumulative Kaplan&#8211;Meier survival curves. <bold>a</bold> Curves for patients with Beclin-1-positive tumors and Beclin-1-negative tumors. <bold>b</bold> Curves for patients with HIF-1&#945;-low tumors and HIF-1&#945;-high tumors. <bold>c</bold> Curves for patients with Beclin-1-positive and HIF-1&#945;-low tumors compared to patients with Beclin-1-negative and HIF-1&#945;-high tumors</p></caption>
###xml 1079 1079 1051 1051 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="12253_2008_9143_Fig2_HTML" id="MO2"/>
###xml 732 1079 720 1051 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="30">Cumulative Kaplan&#8211;Meier survival curves. <bold>a</bold> Curves for patients with Beclin-1-positive tumors and Beclin-1-negative tumors. <bold>b</bold> Curves for patients with HIF-1&#945;-low tumors and HIF-1&#945;-high tumors. <bold>c</bold> Curves for patients with Beclin-1-positive and HIF-1&#945;-low tumors compared to patients with Beclin-1-negative and HIF-1&#945;-high tumors</p></caption><graphic position="anchor" xlink:href="12253_2008_9143_Fig2_HTML" id="MO2"/></fig>
###xml 125 132 <span type="species:ncbi:9606">patient</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
###xml 591 599 <span type="species:ncbi:9606">patients</span>
###xml 792 800 <span type="species:ncbi:9606">patients</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
###xml 951 959 <span type="species:ncbi:9606">patients</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
The median follow-up period was 33.5 months with a range from 11 to 56 months. The 1-, 2- and 3-year survival for the entire patient group was 95.8%, 82.9% and 56.1%, respectively. The survival rate of the Beclin-1-positive group was better than that of the Beclin-1-negative group (Fig. 2a). Furthermore, there was a tendency toward a poorer outcome in patients with HIF-1alpha-high tumors compared with that in patients with HIF-1alpha-low tumors, however, differences were not statistically significant (Fig. 2b). Bivariate analysis was also assessed in 37 patients. The survival rate of patients with Beclin-1-positive and HIF-1alpha-low tumors (n = 24) was significantly higher than that of the other group (n = 13) (Fig. 2c). Fig. 2Cumulative Kaplan-Meier survival curves. a Curves for patients with Beclin-1-positive tumors and Beclin-1-negative tumors. b Curves for patients with HIF-1alpha-low tumors and HIF-1alpha-high tumors. c Curves for patients with Beclin-1-positive and HIF-1alpha-low tumors compared to patients with Beclin-1-negative and HIF-1alpha-high tumors
###end p 29
###begin p 30
###xml 41 42 41 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 200 201 192 193 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 136 144 <span type="species:ncbi:9606">patients</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
Cumulative Kaplan-Meier survival curves. a Curves for patients with Beclin-1-positive tumors and Beclin-1-negative tumors. b Curves for patients with HIF-1alpha-low tumors and HIF-1alpha-high tumors. c Curves for patients with Beclin-1-positive and HIF-1alpha-low tumors compared to patients with Beclin-1-negative and HIF-1alpha-high tumors
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 297 298 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 524 529 <span type="species:ncbi:9606">human</span>
###xml 721 726 <span type="species:ncbi:9606">human</span>
Study showed that malignant cells frequently displayed lower levels of basal autophagic activity than their normal counterparts and failed to increase autophagic activity; in addition, Beclin-1, an autophagy execution protein, was viewed as a tumor suppressor protein [18]. In 1999, Liang et al. [8] found that in 56% of breast cancers there was a significant loss of Beclin-1 protein expression in cancer cells compared to normal breast epithelial cells, later studies reported that Beclin-1 was monoallelically deleted in human prostate, cervical and ovarian cancers and was expressed at reduced levels in those tumors [6, 8, 19]. Miracco et al. [20] recently examined the expression of Beclin-1 protein in 212 primary human brain tumors, in most high-grade astrocytic, ependymal neoplasms and atypical meningiomas they found a decrease of Beclin-1 protein expression that was, instead, high in the majority of low-grade tumors and in medulloblastomas. Which indicates that Beclin-1 expression is related to the aggressiveness of brain tumors.
###end p 32
###begin p 33
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1183 1184 1183 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
Furthermore, controversy regarding the roles of autophagy in cancer has been emerged, studies showed that Beclin-1 play different roles in cell death and cell survival depending on the cellular context [21-23]. Koneri and his colleagues [24] investigated the function of Beclin-1 gene in colorectal cancer cell lines, transfection of the low Beclin-1 gene-expressing colon cancer cell line with the Beclin-1 gene resulted in cell growth inhibition, they concluded that Beclin-1 can inhibit the growth of colorectal cancer cells. Wang et al. [18] detected the role of Beclin-1 in HeLa cells using RNA interference and they found that overexpression of Beclin-1 promoted the autophagy cell death but siRNA against Beclin-1 transfectants promoted the cell proliferation. These examples favor a cancer-killing role for autophagy, overexpression of Beclin-1 induces cell death and defection of autophagy may be an important mechanism in tumorigenesis. However, Amaravadi [25] presented results supporting the idea that autophagy can protect tumor cells from cell death stimuli. Daniel [23] discovered that blockade of Beclin-1 expression aggravates cell death in HepG2 cells. Ahn et al. [9] investigated Beclin-1 protein expression in colorectal and gastric carcinoma tissues, there was increased expression of Beclin-1 in the malignant colorectal and gastric epithelial cells compared to their normal mucosal epithelial cells. These studies provide evidence that autophagy serves as a survival pathway in tumor cells.
###end p 33
###begin p 34
We detected Beclin-1 protein in squmous cell carcinoma tissues of esophagus for the first time and found that there was a loss of Beclin-1 protein expression in 33% of ESCCs compared to normal esophageal epithelial cells. Moreover, Beclin-1 immunoreactivity was correlated significantly with depth of invasion, lymph node metastasis and clinical stage, the survival curve of the Beclin-1 negative group was worse than that of the Beclin-1 positive group. These findings may indicate that Beclin-1 plays an important role in development and progression of ESCC and is a factor significantly influencing overall survival rate.
###end p 34
###begin p 35
###xml 247 249 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 251 253 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 255 257 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 393 395 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 397 399 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 374 381 <span type="species:ncbi:9606">patient</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
###xml 927 935 <span type="species:ncbi:9606">patients</span>
Studies revealed that HIF-1alpha expression was absent in most normal tissues, and in human tumors, overexpression of HIF-1alpha activated metabolic and pathogenic pathways that were related to tumor angiogenesis, growth, invasion and metastasis [10, 26, 27]. Moreover, HIF-1alpha expression may play an important role in the progression of ESCC and is associated with poor patient prognosis [11, 12]. In the present study, HIF-1alpha immunoreactivity was not detected in normal squamous esophageal epithelial cells and HIF-1alpha expression was correlated significantly with differentiation, depth of invasion, and clinical stage of ESCC. Our findings are consistent with results from these previous studies. There was a tendency for shorter survival in patients with high HIF-1alpha expression, but this correlation did not reach statistical significance, probably owing to short periods of follow-up and the small number of patients enrolled in our study.
###end p 35
###begin p 36
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1078 1080 1078 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1558 1560 1558 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1222 1227 <span type="species:ncbi:10090">mouse</span>
Certain environmental cues (such as starvation, low oxygen, hormonal stimulation) activate signalling pathways that increase autophagy, which can either remove defective structures or be as a means of providing macromolecules for energy generation. HIF-1 activates transcription and plays a critical role in oxygen homeostasis [28]. The relationship between autophagy and hypoxia has been interpreted. Previous study showed that autophagy is associated with hypoxia during cardiac ischemia and metabolic stress as a survival mechanism [29]. Azad et al. [14] recently analyzed glioma cell lines, breast cancer cell lines and embryonic cell line for cell death response in hypoxia. Under hypoxic conditions, cell lines induced an autophagic response and underwent cell death. By knocking down the autophagy protein Beclin-1, hypoxia-induced cell death was reduced, hypoxia-induced cell death was also reduced upon treatment with the autophagy inhibitor 3-methyladenine. This demonstrated that autophagic cell death is induced by hypoxia in cancer cells. Zhang and his colleagues [15] found that mitochondrial autophagy is an adaptive metabolic response which is necessary to maintain redox homeostasis and cell survival. In mouse embryo fibroblasts, HIF-1 induces expression of BNIP3, which triggers selective mitochondrial autophagy. Hypoxia can induce mitochondrial autophagy and this process requires the HIF-1-dependent expression of BNIP3 and the constitutive expression of Beclin-1. Which suggests a close relationship exists between Beclin-1 and HIF-1 [30].
###end p 36
###begin p 37
There have been no reports on the association between Beclin-1 and HIF-1alpha expression. Interestingly, Beclin-1 expression was associated with HIF-1alpha expression in our immunohistochemical analysis. HIF-1alpha expression was high while there was reduced expression of Beclin-1 in late stage of ESCC, the survival curve of the Beclin-1 negative and high-HIF-1alpha group was worse than that of the Beclin-1 positive and low-HIF-1alpha group. This study indicates that Beclin-1 and HIF-1alpha proteins may play important roles in the progression of ESCC and are factors significantly influencing overall survival rate. There was a tendency of Beclin-1-induced autophagy inhibition by high expression of HIF-1alpha, which promotes tumor progression. Additional studies are needed to clarify these association.
###end p 37
###begin p 38
###xml 181 186 <span type="species:ncbi:9606">human</span>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
In conclusion, we found that Beclin-1 expression is associated with HIF-1alpha expression. The Beclin-1 and HIF-1alpha proteins appear to play important roles in the progression of human ESCC. Measuring Beclin-1 and HIF-1alpha expression may contribute to a better understanding of the prognosis of patients with ESCC, at least in a subset of patients who had not received preoperative chemoradiotherapy. Beclin-1 can be a potential target for the treatment of ESCCs.
###end p 38
###begin p 39
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
Programmed cell death. Apoptosis and alternative deathstyles
###end article-title 41
###begin article-title 42
Death by design: apoptosis, necrosis and autophagy
###end article-title 42
###begin article-title 43
Autophagy: dual roles in life and death?
###end article-title 43
###begin article-title 44
Autophagy and cancer
###end article-title 44
###begin article-title 45
###xml 25 38 <span type="species:ncbi:11034">Sindbis virus</span>
Protection against fatal Sindbis virus encephalitis by beclin 1, a novel Bcl-2 interacting protein
###end article-title 45
###begin article-title 46
Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21
###end article-title 46
###begin article-title 47
Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor
###end article-title 47
###begin article-title 48
Induction of autophagy and inhibition of tumorigenesis by beclin 1
###end article-title 48
###begin article-title 49
Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers
###end article-title 49
###begin article-title 50
Hypoxia-inducible factor (HIF1alpha and HIF2alpha), angiogenesis and chemoradiotherapy outcome of squamous cell head-and-neck cancer
###end article-title 50
###begin article-title 51
###xml 117 122 <span type="species:ncbi:9606">human</span>
Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer
###end article-title 51
###begin article-title 52
###xml 145 150 <span type="species:ncbi:9606">human</span>
Expression of hypoxia-inducible factor (HIF)-1 alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma
###end article-title 52
###begin article-title 53
Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung
###end article-title 53
###begin article-title 54
Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3
###end article-title 54
###begin article-title 55
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia
###end article-title 55
###begin article-title 56
Mitochondrial autophagy: life and breath of the cell
###end article-title 56
###begin article-title 57
TNM classification of malignant tumors, fifth Edition, Union Internationale Contre le Cancer and the American Joint Committee on Cancer
###end article-title 57
###begin article-title 58
Autophagy as a cell death and tumor suppression mechanism
###end article-title 58
###begin article-title 59
Beclin 1-mediated macroautophagy involves regulation of caspase-9 expression in cervical cancer HeLa cells
###end article-title 59
###begin article-title 60
###xml 58 63 <span type="species:ncbi:9606">human</span>
Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours
###end article-title 60
###begin article-title 61
Beclin 1 augmented cis-diamminedichloroplatinum induced apoptosis via enhancing caspase-9 activity
###end article-title 61
###begin article-title 62
Autophagy: is it cancer's friend or foe?
###end article-title 62
###begin article-title 63
Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells
###end article-title 63
###begin article-title 64
Beclin 1 gene inhibits tumor growth in colon cancer cell lines
###end article-title 64
###begin article-title 65
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
###end article-title 65
###begin article-title 66
###xml 60 65 <span type="species:ncbi:9606">human</span>
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
###end article-title 66
###begin article-title 67
Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer
###end article-title 67
###begin article-title 68
###xml 39 40 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1alpha
###end article-title 68
###begin article-title 69
Harnessing the hypoxia-inducible factor in cancer and ischemic disease
###end article-title 69
###begin article-title 70
HIF regulation of chondrocyte apoptosis: induction of the autophagic pathway
###end article-title 70

